(11bS)-N-(Diphenylmethyl)-N-(i-propyl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine, 97%, 100mg

2-(1-AMINOCYCLOBUTYL)ACETONITRILE, 95.0%, 100mg

3-(tert-Butyl)-4-(2-methoxyphenyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, 95%, 1g

Flat flange reaction vial, cylindrical, graduated, with tempering jacket GL connecting piece, DN 100, 500 ml, 130 mm, 1 Piece

(2S,3S)-4-(Anthracen-9-yl)-3-(tert-butyl)-2-(2-methoxypropan-2-yl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, 97%, 1g

(2-Amino-5-bromophenyl)methanol, 98.0%, 10g

Sodium sulfamate, 98.0%, 25g

1-(5-AMINOINDOLIN-1-YL)-2,2,2-TRIFLUOROETHANONE, 95.0%, 5g

4-Amino-2,6-dichloronicotinic acid, 95%, 250mg

Isopropyl palmitate, min. 90%, for synthesis, 500 ml, plastic packaging.

(4-Methyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl]-methanone, 97.0%, 10g

2-(4-CHLOROPHENYL)-3-METHYL-N-(THIAZOL-2-YL)BUTANAMIDE, 97%, 50mg

7-Chloro-2,4-dimethyl-[1,8]naphthyridine, 95.0%, 1g